A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

OrthoGrid Systems and nView medical Partnering Annnounce Partnership

Announced today, nView medical, a leading innovator in 3D medical imaging, and OrthoGrid Systems, a global MedTech leader offering intraoperative alignment technologies, are partnering to provide integrated solutions that increase surgical accuracy and OR efficiency and improve patient outcomes.

As the first step for implementation, the companies are executing a proof of concept for a periacetabular osteotomy (PAO) procedure, and, after completion, will expand to additional musculoskeletal procedures. PAO surgery aims to preserve the hip joint by repositioning the native acetabulum, a complex pediatric joint preservation surgery that aims to reduce or eliminate the risk of a future total hip replacement. OrthoGrid offers the first PAO-specific, imaging-based, surgical navigation application on the market.

“Many problems in orthopedic surgery are 3D problems. Currently, they are solved based on 2D imaging data,” says Dr. Chris Peters, Professor of Orthopaedics at the University of Utah and a renowned hip preservation specialist. “Being able to merge OrthoGrid’s Hip Preservation application with nView’s real-time, 3D, intraoperative imaging data would bring new and valuable information during critical surgical steps, such as the acetabular osteotomy and positioning.”

Both nView medical and OrthoGrid technologies are AI-driven, open platforms designed to work within the surgical theater to improve accuracy, workflow efficiency, and patient outcomes. With the nView 3D imaging data, planning can be achieved intraoperatively, reducing the need for preoperative planning. Similarly, postoperative alignment verification via x-rays may be avoided, and overall radiation exposure to young patients is expected to reduce drastically.

“We are thrilled to engage in this partnership with OrthoGrid, as we truly have aligned company missions: To enhance surgeons’ experience in the OR while simultaneously working to improve patient outcomes,” said Cristian Atria, Founder and CEO at nView Medical. “OrthoGrid’s expert knowledge of procedural steps and intraoperative problem-solving, along with their commitment to AI-driven, imaging-based automation, is an intuitive next step to further expand the opportunity behind real-time, 3D images. We look forward to seeing the immense impact combining these two innovations will have on musculoskeletal procedures in the years to come.”

“This partnership combines two technological needs within intraoperative imaging: Real-time, 3D imaging, and procedural decision making into one unique solution,” said Edouard Saget, Co-Founder, and Co-CEO at OrthoGrid Systems. “We seek to optimize the value equation in orthopedics, one of OrthoGrid’s long-term commitments. By integrating our applications within nView’s 3D imaging system, we are consolidating the number of devices required in the operating room, thus improving operating room efficiency, staff training, and the overall value proposition to the hospital. At the end of the day, we’re always working to make surgeons’ experience in the OR as seamless as possible.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy